B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.
AIDS Vaccines
/ immunology
Amino Acid Sequence
/ genetics
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ immunology
B-Lymphocytes
/ immunology
Broadly Neutralizing Antibodies
/ immunology
CD4 Antigens
/ immunology
Gene Knock-In Techniques
/ methods
Germinal Center
/ immunology
HIV Antibodies
/ immunology
HIV Antigens
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Mice
Mice, Inbred Strains
Mice, Transgenic
Precursor Cells, B-Lymphoid
/ immunology
Receptors, Antigen, B-Cell
/ immunology
Vaccination
/ methods
HIV
germinal center
germline targeting
immunodominance
vaccine
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
pubmed:
3
9
2020
medline:
28
10
2020
entrez:
3
9
2020
Statut:
ppublish
Résumé
Animal models of human antigen-specific B cell receptors (BCRs) generally depend on "inferred germline" sequences, and thus their relationship to authentic naive human B cell BCR sequences and affinities is unclear. Here, BCR sequences from authentic naive human VRC01-class B cells from healthy human donors were selected for the generation of three BCR knockin mice. The BCRs span the physiological range of affinities found in humans, and use three different light chains (VK3-20, VK1-5, and VK1-33) found among subclasses of naive human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs). The germline-targeting HIV immunogen eOD-GT8 60mer is currently in clinical trial as a candidate bnAb vaccine priming immunogen. To attempt to model human immune responses to the eOD-GT8 60mer, we tested each authentic naive human VRC01-class BCR mouse model under rare human physiological B cell precursor frequency conditions. B cells with high (HuGL18
Identifiants
pubmed: 32873644
pii: 2004489117
doi: 10.1073/pnas.2004489117
pmc: PMC7502816
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Broadly Neutralizing Antibodies
0
CD4 Antigens
0
HIV Antibodies
0
HIV Antigens
0
Receptors, Antigen, B-Cell
0
VRC01 monoclonal antibody
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22920-22931Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI145762
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI125179
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128836
Pays : United States
Informations de copyright
Copyright © 2020 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: W.R.S. is an inventor on a patent application submitted by IAVI and The Scripps Research Institute that covers the eOD-GT8 immunogen. W.R.S. is involved as a principal investigator of a human clinical trial involving eOD-GT8 60mer (G001). As part of that involvement, W.R.S. is privy to certain clinical trial data, and he was forbidden from sharing that data with the authors of this study during the course of this HuGL study, as is standard for blinded clinical trials. Any conclusions in this manuscript regarding relationships between HuGL mouse models and humans were made by the other authors, without input from W.R.S. related to any clinical trial activities.
Références
J Immunol. 2011 Oct 1;187(7):3785-97
pubmed: 21908739
J Immunol. 2013 Sep 15;191(6):3186-3191
pubmed: 23940276
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Cell Rep. 2019 Dec 3;29(10):3060-3072.e7
pubmed: 31801073
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Immunol Rev. 2017 Jan;275(1):49-61
pubmed: 28133798
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
J Exp Med. 2018 Oct 1;215(10):2686-2695
pubmed: 30181412
Curr Opin Immunol. 2018 Aug;53:209-216
pubmed: 30190230
Cell. 2016 Sep 8;166(6):1471-1484.e18
pubmed: 27610571
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Curr Opin Immunol. 2017 Apr;45:21-30
pubmed: 28088708
Cell. 2015 Jun 18;161(7):1505-15
pubmed: 26091035
Science. 2016 Sep 30;353(6307):1557-1560
pubmed: 27608668
Curr Opin Immunol. 2016 Apr;39:59-67
pubmed: 26799208
Sci Transl Med. 2018 May 16;10(441):
pubmed: 29769285
Nature. 2019 Jun;570(7762):468-473
pubmed: 31142836
Cell. 2016 Sep 8;166(6):1459-1470.e11
pubmed: 27610570
PLoS Pathog. 2019 Sep 17;15(9):e1008026
pubmed: 31527908
Annu Rev Immunol. 2017 Apr 26;35:255-284
pubmed: 28142324
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Cell. 2018 Jun 14;173(7):1783-1795.e14
pubmed: 29731169
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748
pubmed: 29666227
PLoS Pathog. 2013;9(5):e1003342
pubmed: 23658524
Immunity. 2016 Nov 15;45(5):1108-1121
pubmed: 27851912
Retrovirology. 2018 Sep 5;15(1):61
pubmed: 30185183
J Immunol. 2013 Sep 15;191(6):3179-85
pubmed: 23940273
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Cell. 2015 Oct 22;163(3):545-8
pubmed: 26496601
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
Immunity. 2018 Dec 18;49(6):1162-1174.e8
pubmed: 30552024
Immunity. 2016 Mar 15;44(3):542-552
pubmed: 26948373
J Exp Med. 2013 Apr 8;210(4):655-63
pubmed: 23530120
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Immunity. 2019 Oct 15;51(4):735-749.e8
pubmed: 31563464
Science. 2015 Jul 10;349(6244):156-61
pubmed: 26089355
Immunology. 2017 Dec;152(4):602-612
pubmed: 28746783
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Immunity. 2016 Apr 19;44(4):939-50
pubmed: 27067056
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
EMBO J. 2018 Sep 14;37(18):
pubmed: 30087111
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):
pubmed: 28159875
Trends Immunol. 2018 Jul;39(7):549-561
pubmed: 29789196
Cold Spring Harb Perspect Biol. 2018 May 1;10(5):
pubmed: 28630079
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Nature. 2019 Nov;575(7781):119-129
pubmed: 31695203
Immunity. 2019 Jul 16;51(1):141-154.e6
pubmed: 31315032
J Immunol. 2013 Sep 1;191(5):2538-50
pubmed: 23918977